NASDAQ:PRTK Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free PRTK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.19▼$2.2450-Day Range$2.17▼$2.2352-Week Range$1.29▼$3.65Volume4.76 million shsAverage Volume724,253 shsMarket Capitalization$127.82 millionP/E RatioN/ADividend YieldN/APrice Target$3.58 Stock AnalysisStock Analysis Get Paratek Pharmaceuticals alerts: Email Address Paratek Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside60.3% Upside$3.58 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.98Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.55 out of 5 starsMedical Sector5071st out of 5,424 stocksBiotechnology Industry37th out of 60 stocks 3.0 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageParatek Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PRTK. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreParatek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.Environmental SustainabilityThe Environmental Impact score for Paratek Pharmaceuticals is -2.98. Previous Next N/A News and Social Media Coverage Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details PRTK Stock News HeadlinesMarch 5, 2024 | markets.businessinsider.comParatek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPsFebruary 24, 2024 | benzinga.comMira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and DatesMay 4, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.October 5, 2023 | finance.yahoo.comParatek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023September 21, 2023 | finance.yahoo.comNovo Holdings closes $462 mln acquisition of Paratek PharmaceuticalsSeptember 21, 2023 | finance.yahoo.comGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.September 19, 2023 | finance.yahoo.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the companySeptember 18, 2023 | bizjournals.comParatek Pharmaceuticals shareholders approve $462M buyout dealMay 4, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.September 18, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 12, 2023 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 7, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsAugust 10, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTKAugust 7, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)August 4, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) ForecastsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionJuly 27, 2023 | seekingalpha.comPRTK Paratek Pharmaceuticals, Inc.July 11, 2023 | finance.yahoo.comNexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalJuly 11, 2023 | msn.comHC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral RecommendationJuly 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)July 10, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxJuly 6, 2023 | msn.comParatek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16June 27, 2023 | msn.comParatek antibiotic Nuzyra to receive EU orphan drug statusJune 27, 2023 | msn.comParatek investor NexPoint warns it may vote against takeover dealJune 27, 2023 | finance.yahoo.comParatek Pharmaceuticals Acknowledges Receipt of NexPoint LetterJune 27, 2023 | finance.yahoo.comNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalSee More Headlines Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today5/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees268Year Founded1996Price Target and Rating Average Stock Price Target$3.58 High Stock Price Target$5.00 Low Stock Price Target$2.15 Potential Upside/Downside+60.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,570,000.00 Net Margins-35.44% Pretax Margin-35.35% Return on EquityN/A Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.46 Sales & Book Value Annual Sales$160.27 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.72Miscellaneous Outstanding Shares57,320,000Free Float52,736,000Market Cap$127.82 million OptionableOptionable Beta1.70 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Michael F. Bigham CPA (Age 65)CPA, M.B.A., MBA, Exec. Chairman Comp: $954.39kDr. Evan Loh FACC (Age 64)FAHA, M.D., CEO & Director Comp: $1.14MMr. Adam Woodrow (Age 56)Pres & Chief Commercial Officer Comp: $763.51kMs. Sarah Higgins (Age 48)VP of Fin., Controller & Principal Accounting Officer Mr. William M. Haskel (Age 61)Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. Mr. Jonathan LightDeputy Gen. Counsel & Chief Compliance OfficerMs. Karen McGrathChief People OfficerMr. Randall B. Brenner (Age 50)Chief Devel. & Regulatory Officer More ExecutivesKey CompetitorsNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEFibroGenNASDAQ:FGENHookipa PharmaNASDAQ:HOOKKezar Life SciencesNASDAQ:KZRView All CompetitorsInsidersMichael BighamSold 31,250 sharesTotal: $68,750.00 ($2.20/share)Evan LohSold 48,967 sharesTotal: $107,727.40 ($2.20/share)William M HaskelSold 34,526 sharesTotal: $75,957.20 ($2.20/share)Randall B BrennerSold 27,603 sharesTotal: $60,726.60 ($2.20/share) PRTK Stock Analysis - Frequently Asked Questions Should I buy or sell Paratek Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares. View PRTK analyst ratings or view top-rated stocks. What is Paratek Pharmaceuticals' stock price target for 2024? 2 Wall Street analysts have issued 12 month target prices for Paratek Pharmaceuticals' stock. Their PRTK share price targets range from $2.15 to $5.00. On average, they expect the company's stock price to reach $3.58 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to analysts' expectations of $22.98 million. During the same quarter last year, the firm earned ($0.46) earnings per share. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL). This page (NASDAQ:PRTK) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.